PFIZER stock news on Anadi Algo News

Wednesday, April 29, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|2 matching stories

PFIZER Share Price, Latest News & Sentiment

Latest AI-analyzed news for PFIZER, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

PFIZER News Today

Emerging stock coverage

The broader market has been volatile, with Nifty50 recently trading below 24,000, influenced by global sentiment and oil prices. Individual stock technical strength, like the RSI upswing, offers specific trading opportunities amidst this uncertainty.

Coverage
2
recent stories
Sources
2
distinct publishers
Bias Split
2 bullish / 0 bearish
0 neutral stories
Window
43d
recent coverage span
Saved Quote Snapshot

Pfizer Limited

Last Updated
29 Apr 2026
Price
Rs 4,781.7
-0.80%
52W Range
Rs 4,100.1 - Rs 5,993
exchange snapshot
PE / VWAP
PE 25.83
VWAP Rs 4,795.77
Trend Read
mixed
EMA stack mixed
Business Context
Industry: Pharmaceuticals
Sector Trail: NIFTY 500
Listing Date: 1999-04-28
Market Structure
F&O Eligible: No
Indices: NIFTY 500, NIFTY MIDSMALL HEALTHCARE, NIFTY MIDSMALLCAP 400
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 31 Dec 2024

Non-Consolidated results
What This Quarter Says

Pfizer's latest filing shows a revenue of Rs 537.99 crore and a profit of Rs 127.6 crore. This information is on record. These numbers tell us how much money the company made and how much profit was left after expenses.

Revenue
Rs 537.99 cr
down 8.6% vs previous filing
Profit
Rs 127.6 cr
down 19.4% vs previous filing
EPS / Finance Cost
EPS 27.89
Finance cost Rs 1.51 cr
Filing Context
Filed 31 Jan 2025, 11:07 pm
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 537.99 cr, down 8.6% vs previous filing.
  • Profit this quarter: Rs 127.6 cr, down 19.4% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 27.89.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

Related Stocks

PFIZER FAQ

Why is PFIZER in the news right now?

PFIZER has appeared across 2 recent stories from 2 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is PFIZER coverage bullish or bearish right now?

PFIZER coverage is currently leaning bullish, with 2 bullish, 0 bearish, and 0 neutral analyzed stories in the recent window.

Which themes are moving with PFIZER?

Recent PFIZER coverage is clustering around Healthcare and pharma. Related names showing up alongside PFIZER include SYNGENE.

How should I use this PFIZER news page?

Use this page as a coverage hub for PFIZER: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use PFIZER coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
Focus on identifying the other five Nifty500 stocks with bullish RSI crossovers and consider long positions with tight stop-losses, targeting short-term momentum plays.|Quick check: PFIZER neutral (+0.1% 1d), NIFTY neutral.
ValuePickrabout 1 month ago

Sai Life Sciences - India's WuXi?

The CRDMO sector in India is experiencing significant growth, driven by outsourcing trends from global pharmaceutical companies. Companies with strong client relationships and consistent growth are highly valued.

Investors should monitor the CRDMO space for companies demonstrating strong growth and client acquisition, as this indicates robust business fundamentals.|Quick check: SYNGENE bearish bias (oversold), SUNPHARMA neutral (-1.4% 1d).